FNB vs GBCI

FNB presents a stark contrast between deep value and deteriorating financial health, highlighted by a weak Piotroski F-Score of 2/9. While the stock is significantly undervalued relative to its Graham Number ($26.4) and Intrinsic Value ($47.79), and trades below book value (P/B 0.92), the deterministic health markers are concerning. Strong YoY earnings growth (18.8%) and a consistent track record of earnings beats provide a bullish fundamental backdrop, but these are offset by bearish insider sentiment and a complete lack of technical momentum. The overall outlook is neutral as the value proposition is currently fighting against poor operational health signals.

GBCI presents a stark contrast between aggressive growth and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 41.4% and earnings growth of 31.1%, the underlying financial health metrics are concerning. The stock currently trades at a premium to its Graham Number ($38.1) but below its growth-based intrinsic value ($58.7). The high dividend payout ratio of 82.91% combined with a bearish technical trend suggests limited immediate upside despite analyst 'buy' recommendations.